The evolution of surgical treatment for gastrointestinal cancers

Maehara, Yoshihiko; Soejima, Yuji; Yoshizumi, Tomoharu; Kawahara, Nobuaki; Oki, Eiji; Saeki, Hiroshi; Akahoshi, Tomohiko; Ikegami, Toru; Yamashita, Yo Ichi; Furuyama, Tadashi; Sugimachi, Keizō; Harada, Noboru; Tagawa, Tetsuzo; Harimoto, Norifumi; Itoh, Shinji; Sonoda, Hideto; Ando, Koji; Nakashima, Yasuhiro; Nagao, Yuhei; Yamashita, Nami; Kasagi, Yuta; Yukaya, Takafumi; Kurihara, Toshio; Tsutsumi, Ryosuke; Takamori, Shinkichi; Sasaki, Shun; Ikeda, Tetsuo; Yonemitsu, Yoshikazu; Fukuhara, Takasuke; Kitao, Hiroyuki; Iimori, Makoto; Kataoka, Yuki; Wakasa, Takeshi; Suzuki, Masami; Teraishi, Koji; Yoshida, Yoshinobu; Mori, Masaki

doi:10.1007/s10147-019-01499-7

Cited by 8 publications

(6 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…From the 27 identified articles, 21 were included. Six communications were excluded from the analysis -four case reports [9][10][11][12]GmbH & Co. KG, Tuttlingen, Germany, one review on the evolution of treating gastrointestinal cancers [13], and one containing no data about AL rate with ICG [14]during colorectal resections. Methods: FLER analysis and visualization was performed in 22 patients (diverticulitis n = 17; colorectal cancer n = 5.…”

Section: Literature Searchmentioning

confidence: 99%

Review on Anastomotic Leak Rate after ICG Angiography during Minimally Invasive Colorectal Surgery

Yotsov

Karamanliev

Maslyankov

et al. 2021

Journal of Biomedical and Clinical Research

View full text Add to dashboard Cite

Summary Colorectal cancer is the 3rd most common type of cancer worldwide. The most devastating complication after colorectal surgery remains the anastomotic leak (AL). Many techniques have been developed to reduce its rate. One such new method is perfusion angiography using indocyanine green (ICG). A literary search in PUBMED on 1.03.2021 for full-text English articles published between 2014 and 2021 was performed. ICG, colorectal cancer, and angiography were the keywords we used. The review was performed following the recommendations of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. The literature search yielded 27 results when searching the database of PUBMED with the above keywords. Twenty-one out of 27 identified articles were included. Six were excluded from the analysis – four case reports, one review on the evolution of treating gastrointestinal cancers, and one containing no information on AL rate with ICG. One included article was RCT, sixteen were cohort studies, and four were meta-analyses or reviews. All articles reported a reduction in the anastomotic leak rate. However, the reduction was significant only in nine of them. Anastomotic leak is a severe complication and a subject of extensive research. Perfusion angiography with ICG is a step towards predicting and preventing AL, although it does not guarantee success in all cases.

show abstract

Section: Literature Searchmentioning

confidence: 99%

Review on Anastomotic Leak Rate after ICG Angiography during Minimally Invasive Colorectal Surgery

Yotsov

Karamanliev

Maslyankov

et al. 2021

Journal of Biomedical and Clinical Research

View full text Add to dashboard Cite

show abstract

“…Statistics unveil that tumors undergo continuous development and progression, which is the reason for attracting much recent research toward the study and manipulation of this life‐threatening disease. In Japan, over one million new cancer cases are diagnosed each year, [ 1 ] and the annual diagnosis of new cases is projected to reach 23 million by 2030. [ 2 ] The worldwide estimation for cancer‐related deaths in the year 2012 was 8 million.…”

Section: Introductionmentioning

confidence: 99%

“…[ 10 ] Among the solid organs, tumors of the gastrointestinal system account for more than 40% of cancer‐related deaths. [ 1 ] In 2018, the four leaders of death from cancer worldwide belonged to the malignancies in the lung, colorectal (colorectal cancer [CRC]), stomach, and liver. [ 3 ] The content in Table 1 gives an overview of the current regional and worldwide prevalence of solid cancers along with their rate of mortality and survival.…”

Section: Introductionmentioning

confidence: 99%

The current knowledge concerning solid cancer and therapy

Najafi

Majidpoor

Toolee

et al. 2021

J Biochem & Molecular Tox

View full text Add to dashboard Cite

Solid cancers comprise a large number of new cases and deaths from cancer each year globally. There are a number of strategies for addressing tumors raised from solid organs including surgery, chemotherapy, radiotherapy, targeted therapy, immunotherapy, combinational therapy, and stem cell and extracellular vesicle (EV) therapy. Surgery, radiotherapy, and chemotherapy are the dominant cures, but are not always effective, in which even in a localized tumor there is a possibility of tumor relapse after surgical resection. Over half of the cancer patients will receive radiotherapy as a part of their therapeutic schedule. Radiotherapy can cause an abscopal response for boosting the activity of the immune system outside the local field of radiation, but it may also cause an unwanted bystander effect, predisposing nonradiated cells into carcinogenesis. In the context of immunotherapy, immune checkpoint inhibition is known as the standard‐of‐care, but the major concern is in regard with cold cancers that show low responses to such therapy. Stem‐cell therapy can be used to send prodrugs toward the tumor area; this strategy, however, has its own predicaments, such as unwanted attraction toward the other sites including healthy tissues and its instability. A substitute to such therapy and quite a novel strategy is to use EVs, by virtue of their stability and potential to cross biological barriers and long‐term storage of contents. Combination therapy is the current focus. Despite advances in the field, there are still unmet concerns in the area of effective cancer therapy, raising challenges and opportunities for future investigations.

show abstract

“…Over several decades, innovative strategies have improved the oncologic outcomes of patients with rectal cancer [1], including standardization of total mesorectal excision (TME); preoperative chemoradiotherapy; diagnostic imaging, especially magnetic resonance imaging (MRI); and a multidisciplinary team (MDT) approach. These efforts have contributed to decrease local recurrence rates to around 5% of patients with locally advanced rectal cancer (LARC), as reported by some prospective studies [2,3].…”

Section: Introductionmentioning

confidence: 99%

Initial experience of preoperative short-course radiotherapy followed by oxaliplatin-based consolidation chemotherapy for locally advanced rectal cancer

Song

Park

Kang

et al. 2021

Int J Colorectal Dis

View full text Add to dashboard Cite

Purpose: We analyzed the safety and feasibility of preoperative short-course radiotherapy (SCRT) followed by consolidation chemotherapy for patients with locally advanced rectal cancer (LARC). Methods: From April 2018 to May 2019, 19 patients with LACR were treated with SCRT followed by three cycles of consolidation chemotherapy with leucovorin, uorouracil, and oxaliplatin (FOLFOX6) before surgery. Adjuvant chemotherapy relied on oxaliplatin. Tumor response, patient compliance, and toxicities were analyzed. Results: The median age was 60 years (range 44-71), and 16 of the patients were male. The median tumor height was 5 cm (range 0-9) from anal verge. All patients received a total dose of 25 Gy in ve fractions. The number of cycles of FOLFOX6 before surgery was three in 17, four in one, ve in one. Five patients required dose reductions in consolidation chemotherapy. The median interval between initiation of SCRT and surgery was 10.6 weeks (range 8.6-16.4). A pathologic complete response was seen in two patients (11%). Grade III toxicities to the preoperative treatment were seen in ve patients (26%): diarrhea in two, a decreased white blood cell count in one, and anemia in two. Postoperative complications arising within 30 days developed in ve patients (26%). During the median follow-up period of 20.4 months, there was no tumor recurrence. Conclusion: Preoperative SCRT followed by oxaliplatin-based consolidation chemotherapy showed acceptable toxicity and feasibility in patients with LARC. Prospective randomized trials are warranted to verify the e cacy and safety of this treatment strategy compared with conventional long-course concurrent chemoradiotherapy.

show abstract

The evolution of surgical treatment for gastrointestinal cancers

Cited by 8 publications

References 49 publications

Review on Anastomotic Leak Rate after ICG Angiography during Minimally Invasive Colorectal Surgery

Review on Anastomotic Leak Rate after ICG Angiography during Minimally Invasive Colorectal Surgery

The current knowledge concerning solid cancer and therapy

Initial experience of preoperative short-course radiotherapy followed by oxaliplatin-based consolidation chemotherapy for locally advanced rectal cancer

Contact Info

Product

Resources

About